Overall the results in this study suggested that p65 and wild-type p53 counter-acted each other in DLBCL, and that the inhibition of p53 tumor suppressor function by p65 hyperactivation had a significant adverse impact on clinical outcomes. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.